Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 143,900 shares, a decrease of 65.7% from the February 13th total of 419,000 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 7,140,000 shares, the days-to-cover ratio is presently 0.0 days.
Institutional Investors Weigh In On Biomerica
An institutional investor recently raised its position in Biomerica stock. Granahan Investment Management LLC grew its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA – Free Report) by 24.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 658,767 shares of the company’s stock after purchasing an additional 131,306 shares during the quarter. Granahan Investment Management LLC owned approximately 3.59% of Biomerica worth $198,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.28% of the company’s stock.
Biomerica Trading Down 1.5 %
NASDAQ BMRA opened at $0.60 on Thursday. The firm has a market capitalization of $11.08 million, a P/E ratio of -1.78 and a beta of -1.16. The business has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.43. Biomerica has a 12 month low of $0.24 and a 12 month high of $1.27.
Biomerica Company Profile
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Read More
- Five stocks we like better than Biomerica
- Top Biotech Stocks: Exploring Innovation Opportunities
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Financial Services Stocks Investing
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- 3 Stocks to Consider Buying in October
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.